Clinical trials: Epithelial Neoplasms, Malignant
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005818
- Testing
- irinotecan hydrochloride, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase II trial studies ziv-aflibercept in treating and perfusion computed tomography perfusion imaging in predicting response in patients with pancreatic neuroendocrine tumors that have spread to other parts of the body or…
- Trial name
- NCT02101918
- Testing
- Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
The primary purpose of the study is to estimate the maximum tolerated dose of the combination of LDK378 and AUY922. This study will assess the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity…
- Trial name
- NCT01772797
- Testing
- LDK378, AUY922
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Periampullary Carcinoma Resectable, Pancreatic Tumors
New Technique of Pancreaticojejunostomy During Whipple Operation
Following pancreaticoduodenectomy, omental flaps around the pancreatic anastomosis can lower the risk of pancreatic fistula, post-pancreatectomy bleeding, and delayed gastric emptying.
- Conditions
- Periampullary Carcinoma Resectable, Pancreatic Tumors, Duodenal Neoplasms
- Trial name
- whipple (NCT06630910)
- Testing
- Pancreaticojejunostomy without stenting and omental patch, Pancreaticojejunostomy with stenting and omental patch
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Theodor Bilharz Research Institute
Breast Cancer
Eradication of Malignant Carcinoma in the Breast Tissue
The purpose of this study is to confirm the findings of an early study and expand our knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor.
- Trial name
- NCT02286778
- Testing
- Acetogenins
- Volunteers
- 60 people
- Sponsor
- Optimal Health Research
Head and Neck Cancer
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- CAPRA (NCT01333085)
- Testing
- carboplatin, RAD001, paclitaxel
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared…
- Trial name
- IMpower150 (NCT02366143)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 1,202 people
- Sponsor
- Hoffmann-La Roche
Anal Cancer
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00324415
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AIDS Malignancy Consortium
Non Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged…
- Trial name
- NCT00399789
- Testing
- Perifosine
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- AEterna Zentaris
Merkel Cell Carcinoma
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
This is a window-of-opportunity study for patients with resectable Merkel Cell Carcinoma. The aim of this study is to test the activity of a course of chemo-immunotherapy followed by surgery in patients with operable Merkel cell…
- Trial name
- MERCURY (NCT05594290)
- Testing
- Retifanlimab, Cisplatin, Etoposide
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Bladder Cancer, Bladder Carcinoma
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
Bladder preservation in patients with complete response after neoadjuvant chemotherapy will lead to equivalent or superior relapse free rates compared to cystectomy rates from historical controls.
- Conditions
- Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT02145390
- Testing
- Transurethral Resection of the Bladder Tumor & Cystoscopy, Intensity Modulated Radiation Therapy, Expanded Prostate Cancer Index Composite Short Form 12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Carcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer.
- Trial name
- NCT03711890
- Testing
- Optical Coherence Tomography, Therapeutic Conventional Surgery, Laboratory Evaluation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00005997
- Testing
- becatecarin
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma
Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE
This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.
- Trial name
- NCT03731910
- Testing
- MRI
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Seoul National University Hospital
Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
Patients With High-grade Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic…
- Trial name
- NCT07121478
- Testing
- Lurbinectedin 4 MG Injection [Zepzelca]
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- National Cancer Center, Korea
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma
Trial of Tolcapone With Oxaliplatin for Neuroblastoma
The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S.
- Trial name
- NCT02630043
- Testing
- Tolcapone, Oxaliplatin
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Giselle Sholler
Neuroblastoma
Therapy for Children With Neuroblastoma
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell…
- Trial name
- NCT00135135
- Testing
- Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid, Radiation therapy, Surgery, Peripheral Stem cell transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.